Test Price
2,800 AED✅ Home Collection Available
CNTN1 Gene Genetic Test (Compton-North Congenital Myopathy) in UAE | 2800 AED | 2026 DHA Guidelines
تحليل الجين CNTN1 لاعتلال العضلات الخلقي كومبتون-نورث (Compton-North Congenital Myopathy) في الإمارات | 2800 درهم | مبادئ توجيهية 2026 من هيئة الصحة بدبي
Executive Summary
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO‑accredited NGS platform; every variant confirmed with orthogonal methods if required.
- Premium Logistics: Paid hospital‑grade home collection by DHA‑registered phlebotomists, cold‑chain transport for DNA integrity, available 8 AM–11 PM daily.
- Clinical Guidance: Complimentary telephonic post‑test clinical guidance to help you and your doctor interpret results in the context of your personal and family history.
- Insurance Support: Direct billing verification via WhatsApp at +971 54 548 8731.
الملخص التنفيذي
يُقدم هذا الفحص التشخيصي الدقيق تحليلًا كاملًا لجين CNTN1 باستخدام تقنية التسلسل الجيني من الجيل التالي (NGS) لتأكيد الإصابة باعتلال العضلات الخلقي كومبتون-نورث. نضمن أعلى درجات الحساسية التشخيصية بدعم من مختبرنا المعتمد وفق معيار ISO وترخيص هيئة الصحة بدبي، مع خدمة سحب منزلي متميزة واستشارة ما بعد الفحص.
Quick Overview
This targeted NGS test analyzes the entire coding region of the CNTN1 gene to detect causative variants for Compton‑North congenital myopathy, a rare early‑onset muscle disorder. يكشف التحليل الطفرات الممرضة في جين CNTN1 المرتبطة بالاعتلال العضلي الخلقي. Results are typically ready in 3–4 weeks, making it one of the fastest definitive molecular tests available in the UAE.
| Feature | Our CNTN1 NGS Test | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Precision for CNTN1 | 100% coverage of all coding exons ±10 bp, >99.9% sensitivity | 98–99% coverage of CNTN1; may miss deep intronic variants |
| Methodology | Targeted high‑depth NGS (Illumina NovaSeq) with Sanger confirmation | Exome capture + NGS; incidental findings require additional consent |
| Turnaround Time | 3–4 weeks | 6–12 weeks |
| Clinical Report | Gene‑specific, ACMG‑classified variant, genetic counseling note | Broad, may require secondary analysis for single gene |
Physician Insight & Safety Protocol
Dr. Prabhakar Reddy, DHA 61713011, notes: “This NGS test provides powerful molecular confirmation for Compton‑North congenital myopathy, but it must always be correlated with detailed neurological examination, muscle MRI/EMG, and a thorough family pedigree. Genetic diagnosis is a piece of the clinical puzzle; it does not replace the compassionate judgment of your treating physician.”
Medication Warning
Do not discontinue or adjust any prescribed medication without consulting your supervising physician. Genetic test results inform long‑term management but do not provide immediate therapeutic directives. Always maintain your current treatment regimen unless explicitly altered by your specialist.
Safety Exclusion Criteria & Red Flags
- Exclusion: Inability to provide informed consent per UAE law (legal guardian required for minors). Recent blood transfusion or allogeneic stem cell transplant within 2 weeks may compromise DNA purity; inform our team before collection.
- Exclusion: Active severe infection affecting white blood cell count may lead to suboptimal DNA yield; reschedule if febrile >38.5°C.
- Red Flag: If you or your child experience sudden profound muscle weakness, swallowing difficulty, or respiratory distress, seek emergency care immediately – these are not typical complications of blood draw but could signal disease progression.
- Red Flag: Unexpected findings (e.g., variants of uncertain significance, incidental secondary findings) will be reported responsibly; follow‑up genetic counseling is mandatory under UAE CDS Law 2026 for minors.
Patient FAQ & Clinical Guidance
1. What does the CNTN1 NGS test reveal, and why is it needed?
Snippet: The CNTN1 NGS test detects pathogenic variants causing Compton‑North congenital myopathy, confirming the diagnosis at a molecular level and guiding precise genetic counseling. It is recommended when clinical signs (neonatal hypotonia, facial weakness, delayed motor milestones) and family history suggest this specific myopathy.
يكشف اختبار CNTN1 NGS عن الطفرات الجينية المسببة لاعتلال العضلات الخلقي كومبتون-نورث، مما يؤكد التشخيص جزيئيًا ويوجه الاستشارة الوراثية بدقة.
2. How long do results take, and what happens after I receive them?
Snippet: You will receive your definitive report in 3–4 weeks, after which a complimentary telephonic post‑ guidance session with a DHA‑licensed genetic specialist is scheduled to interpret the findings. The report includes ACMG variant classification, clinical significance, and explicit recommendations for follow‑up with your neurologist or pediatrician.
تصلك النتائج النهائية خلال 3–4 أسابيع، تليها جلسة استشارة هاتفية مجانية مع أخصائي جينات مرخص من هيئة الصحة بدبي لشرح التقرير وتوصيات المتابعة.
3. Is home blood collection available, and is it safe for newborns?
Snippet: Yes, our DHA‑accredited mobile phlebotomy team offers hospital‑grade home collection from 8 AM to 11 PM daily, using pediatric butterfly needles ideal for neonates and adhering to strict cold‑chain protocols to preserve DNA integrity. All procedures follow UAE CDS Law 2026 for minors, requiring legal guardian consent.
نعم، نوفر خدمة سحب الدم المنزلي عبر فريق تمريض معتمد من هيئة الصحة بدبي، بما في ذلك استخدام إبر الفراشة المخصصة لحديثي الولادة، مع الالتزام بقانون الخدمات السريرية للأطفال 2026 وإجراءات الحفظ المبرد.
Ready to get tested?
Schedule your home collection or ask for insurance pre‑authorization via WhatsApp.
WhatsApp: +971 54 548 8731ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) | Federal Decree-Law No. 41 of 2024 (Art. 87) | UAE PDPL compliant
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians